Prescient Therapeutics

Prescient Therapeutics Current Liabilities

Current Liabilities of Prescient Therapeutics (PTX.AX) as of Nov 22, 2026.

Current Liabilities

-AUD

Last updated:

Current Liabilities of Prescient Therapeutics is 2026 - AUD. Current Liabilities of Prescient Therapeutics was 2025 - AUD. It decreases by % lower compared to the previous year.

The Prescient Therapeutics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 1999
239,700.00 AUD
Jan 1, 2008
747,553.00 AUD
Jan 1, 2010
781,928.00 AUD
Jan 1, 2013
0.00 AUD
Jan 1, 2014
252,892.00 AUD
Jan 1, 2015
460,433.00 AUD
Jan 1, 2016
832,004.00 AUD
The Prescient Therapeutics Current Liabilities history
YEARCurrent LiabilitiesYoY
832,004.00AUD+80.70%
460,433.00AUD+82.07%
252,892.00AUD—
0.00AUD-100.00%
781,928.00AUD+4.60%
747,553.00AUD+211.87%
239,700.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prescient Therapeutics Stock analysis

What does Prescient Therapeutics do? Prescient Therapeutics Ltd is an Australian biotechnology company focused on developing novel cancer therapies. The company was founded in 2006. Its business model is based on leveraging modern technologies and research findings to develop innovative solutions for cancer treatment. Prescient Therapeutics operates in two segments: drug development and research services. The company collaborates closely with leading scientists and medical institutions to utilize the latest advancements in cancer research and bring new drugs to the market. One of its products, PTX-200, is a novel inhibitor of protein kinase CK2 that has shown efficacy in clinical studies against various types of cancer. Another important product is OmniCAR, a next-generation CAR-T cell therapy that allows for selective recognition and destruction of cancer cells. Prescient Therapeutics aims to solidify its position as a leading provider of innovative cancer treatments through a rigorous validation strategy and collaboration with doctors and patients. The company has made significant progress in the development of new cancer therapies, holding numerous patents and establishing partnerships with leading medical institutions. Its goal is to meet the unmet needs of cancer patients and create a better future for cancer therapy. Prescient Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prescient Therapeutics stock

On Eulerpool you can find the complete historical development of Current Liabilities Prescient Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Prescient Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Prescient Therapeutics

All Key Metrics — Prescient Therapeutics